Jain Anuj, Jain Suruchi, Barasker Swapnil Kumar, Trivedi Saurabh, Gupta Ekta, Kaushal Ashutosh
Department of Anesthesiology, All India Institute of Medical Science, Saket Nagar, Bhopal, Madhya Pradesh, 462020, India.
Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, 462020, India.
Interv Pain Med. 2022 Nov 15;1(4):100159. doi: 10.1016/j.inpm.2022.100159. eCollection 2022 Dec.
Transforaminal epidural steroid injection (TFESI) is commonly used to relieve pain due to intervertebral disc displacements (IDD). Poorly defined selection criteria lead to post procedure dissatisfaction among patients. We aimed to find clinical and magnetic resonance imaging (MRI) predictors for pain relief at 3 months following a TFESI. Poorly defined selection criteria lead to post procedure dissatisfaction among patients.
A retrospective study of 116 patients who had undergone TFESI. Predictors used were - age, duration of symptoms, body mass index, neuropathic character of pain, dermatomal distribution of pain, claudication distance, response to anti-neuropathic medication and extent of nerve root compromise in MRI as per Pfirmann criteria. A relief of 50% or more at the end of 3 months was considered the criterion for significant pain relief from TFESI.
At 3 months, 72% (84/116) had significant pain relief. Dermatomal distribution of pain (73%) and neurogenic claudication (71%) were the most prevalent clinical features. Dermatomal distribution of leg pain, responsiveness to anti-neuropathic medications and a Pfirmann grade 2/3 in MRI were the most important predictors with an odds ratio (OR) of 12.1, < 0.001, OR 6.4, = 0.002 and OR 3.1, = 0.056, respectively. The model was statistically significant χ (3, N = 116) = 43.43, 0.001 and explained 52% variance in the outcome. The model correctly predicted the outcome 85% times.
If a patient has leg pain which is dermatomal in distribution, responds to anti-neuropathic medications and has Pfirmann grade 2/3 in MRI, then chances of more than 50% relief persisting at 3 months after TFESI are significantly better.
经椎间孔硬膜外类固醇注射(TFESI)常用于缓解因椎间盘移位(IDD)引起的疼痛。选择标准不明确导致患者术后满意度不高。我们旨在寻找TFESI术后3个月疼痛缓解的临床和磁共振成像(MRI)预测指标。选择标准不明确导致患者术后满意度不高。
对116例行TFESI的患者进行回顾性研究。使用的预测指标包括——年龄、症状持续时间、体重指数、疼痛的神经病理性特征、疼痛的皮节分布、跛行距离、对抗神经病理性药物的反应以及根据Pfirmann标准在MRI上神经根受压的程度。3个月末疼痛缓解50%或更多被视为TFESI显著缓解疼痛的标准。
3个月时,72%(84/116)的患者疼痛得到显著缓解。疼痛的皮节分布(73%)和神经源性跛行(71%)是最常见的临床特征。腿痛的皮节分布、对抗神经病理性药物的反应以及MRI上Pfirmann分级为2/3是最重要的预测指标,比值比(OR)分别为12.1,P<0.001;OR为6.4,P = 0.002;OR为3.1,P = 0.056。该模型具有统计学意义,χ(3,N = 116)= 43.43,P = 0.001,可解释结果中52%的方差。该模型正确预测结果的概率为85%。
如果患者腿痛呈皮节分布,对抗神经病理性药物有反应,且MRI上Pfirmann分级为2/3,那么TFESI术后3个月持续缓解超过50%的可能性显著更高。